PXSP.L
現在値
0.81GBp変化
--(--)本日のレンジ
-
--52週レンジ
-
1.49∙ 約20分前の相場を表示しています。
前日終値 | 0.81 |
|---|---|
始値 | -- |
出来高 | -- |
3か月平均出来高 | 38.87 |
高値 | -- |
安値 | -- |
52週高値 | 1.49 |
52週安値 | 0.36 |
発行済株式数 | 2,070.82 |
時価総額 | 18.43 |
予想PER | -- |
配当利回り | -- |
Provexis FY Loss Of 424,500 Stg Vs. 533,400 Stg Loss Year Ago
Provexis Says FY Underlying Operating Loss £385,000
Provexis Sees To Report Rev For Year Ended 31 March Of £322k
Provexis plc is engaged in developing and licensing the Fruitflow heart-health functional food ingredient for the global functional food sector. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The Company also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The Company's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.
業種
Biotechnology & Drugs
エグゼクティブリーダーシップ
C. Dawson Buck
Non-Executive Independent Chairman of the Board
Niamh O'Kennedy
Chief Scientific Officer, Executive Director
Ian Ford
Company Secretary, Executive Director
Frederic Boned
Non-Executive Director
株価売上高倍率（過去12カ月） | -- |
|---|---|
株価売上高倍率（過去12カ月） | 52.97 |
株価純資産倍率（四半期） | 22.51 |
株価キャッシュフロー倍率 | -- |
総負債／総資本（四半期） | 0.00 |
長期負債／資本（四半期） | 0.00 |
投資利益率(過去12カ月） | -52.06 |
自己資本利益率（過去12カ月) | -91.21 |
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。